Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHernández Pascual, Cristina
dc.contributor.authorBogdanov , Patricia Monica
dc.contributor.authorGómez-Guerrero, Carmen
dc.contributor.authorSampedro Vida, Joel
dc.contributor.authorSolà Adell, Cristina
dc.contributor.authorEspejo Ruiz, Carmen
dc.contributor.authorGarcía Ramírez, Marta
dc.contributor.authorSimó Canonge, Rafael
dc.date.accessioned2020-02-04T13:37:12Z
dc.date.available2020-02-04T13:37:12Z
dc.date.issued2019-07-24
dc.identifier.citationHernández C, Bogdanov P, Gómez-Guerrero C, Sampedro J, Solà-Adell C, Espejo C, et al. SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Int J Mol Sci. 2019 Jul 24;20(15):3615.
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/11351/4586
dc.descriptionDiabetic retinopathy; Neuroinflammation; Suppressors of cytokine signaling
dc.description.abstractCurrent treatments for diabetic retinopathy (DR) target late stages when vision has already been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters was observed, thus revealing a clear impact of the histological findings on global retinal function. Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal neuroinflammation and early microvascular impairment. These findings could open up a new strategy for the treatment of early stages of DR.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesInternational Journal of Molecular Sciences;20(15)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectRetinopatia diabètica
dc.subjectQuimiocines
dc.subjectRetina - Vasos sanguinis
dc.subject.meshDiabetic Retinopathy
dc.subject.meshSuppressor of Cytokine Signaling Proteins
dc.subject.meshBlood-Retinal Barrier
dc.titleSOCS1-derived peptide administered by eye drops prevents retinal neuroinflammation and vascular leakage in experimental diabetes
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/ijms20153615
dc.subject.decsretinopatía diabética
dc.subject.decsproteínas supresoras de la señalización de citocinas
dc.subject.decsbarrera hematorretinal
dc.relation.publishversionhttps://www.mdpi.com/1422-0067/20/15/3615
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Hernández C, Bogdanov P, Sampedro J, Solà-Adell C, García-Ramírez M, Simó R] Grup de Diabetis i Metabolisme, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Gómez-Guerrero C] Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Renal, Vascular and Diabetes Research Lab, Instituto de Investigacion Sanitaria-Fundación Jimenez Diaz (IIS-FJD), Madrid, Spain. Autonoma University of Madrid (UAM), Madrid, Spain. [Espejo, C] Recerca en Neuroimmunologia clínica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
dc.identifier.pmid31344857
dc.identifier.wos000482383000008
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record